Quick Answer
Apitegromab is an experimental drug that blocks myostatin — a protein that limits muscle growth. In a phase 2 clinical trial called EMBRAZE, published in Nature Medicine on June 8, 2026, people taking apitegromab alongside tirzepatide (Mounjaro) preserved 1.9 kg (4.2 lbs) more lean mass than those taking tirzepatide alone.
That is a 54.9% improvement in muscle retention. And it happened without affecting weight loss — both groups lost about the same amount of total weight.
Apitegromab is not FDA-approved. It is still in clinical trials. But it represents one of the most promising approaches to solving the muscle loss problem on GLP-1 medications.
The Problem: Muscle Loss on GLP-1s
When you lose weight on GLP-1 medications, not all of it is fat. Clinical trials show that 25-40% of weight lost can come from lean muscle mass.
This matters because:
- Muscle drives your metabolism — less muscle means fewer calories burned at rest
- Muscle loss can make you weaker and more tired
- Regaining weight after stopping GLP-1s tends to come back as fat, not muscle
- This is sometimes called "Ozempic body" — people lose weight but feel physically diminished
The muscle loss problem has driven intense research into combination therapies. Apitegromab is the latest and most high-profile entry.
For a deeper look at why muscle loss happens on GLP-1s, see our comprehensive guide to GLP-1 muscle loss.
How Apitegromab Works
Apitegromab is a fully human monoclonal antibody. It targets a specific protein called myostatin.
Myostatin is your body's natural brake on muscle growth. When myostatin binds to its receptor, it tells your muscles to stop growing or to break down. Apitegromab blocks myostatin from activating. With this brake released, your muscles can hold on to tissue even while you are in a calorie deficit.
The mechanism is fundamentally different from GLP-1 drugs. Tirzepatide reduces appetite and slows digestion. Apitegromab tells your muscles to resist breaking down. They work on completely separate systems.
This is also different from bimagrumab, another experimental muscle-preserving drug. Bimagrumab blocks the activin receptor type II (ActRII), which is further downstream in the same general pathway. Apitegromab targets myostatin more directly. See our bimagrumab guide for the comparison.
The EMBRAZE Trial: What the Data Shows
The EMBRAZE study (NCT06445075) was a randomized, double-blind, placebo-controlled phase 2 trial published in Nature Medicine on June 8, 2026.
Trial Design
| Parameter | Details |
|---|---|
| Participants | 102 adults with overweight or obesity |
| Duration | 24 weeks |
| Groups | Tirzepatide + apitegromab (10 mg/kg) vs tirzepatide + placebo |
| Dosing | Tirzepatide weekly injection; apitegromab monthly IV infusion |
| Primary endpoint | Change in lean body mass by DEXA scan at week 24 |
Key Results
| Outcome | Apitegromab + Tirzepatide | Placebo + Tirzepatide |
|---|---|---|
| Lean mass loss | 1.9 kg less loss (54.9% retention) | Baseline |
| Lean mass as % of total weight loss | 14.6% | 30.2% |
| Total body weight loss | Similar between groups | Similar |
| Grip strength | Slightly improved | No change |
| Chair sit-to-stand | Slightly improved | No change |
The headline finding: 1.9 kg (4.2 lbs) more muscle preserved over 24 weeks. Statistically significant (P = 0.001). And total weight loss was essentially the same.
Safety
Adverse events were similar between groups:
- Apitegromab group: 76% experienced any AE
- Placebo group: 71% experienced any AE
- Serious adverse events: 2% in each group
The drug was well tolerated. No new safety signals emerged.
Limitations to Keep in Mind
The trial was relatively small (102 participants). More than 80% were female. People with significant cardiometabolic conditions — including diabetes — were excluded. The study lasted only 24 weeks.
As Dr. Marie Spreckley from Cambridge University noted, these are "encouraging early evidence" but not definitive proof of clinical benefit. Larger, longer studies are needed.
What This Means for GLP-1 Users
If You Are on Tirzepatide (Mounjaro / Zepbound) Today
Apitegromab is not available. Do not expect to get it soon. The EMBRAZE trial used intravenous infusions — not practical for daily use. Researchers are exploring whether a self-injection pen could work, but that is years away.
What You Can Do Right Now
The proven strategies for muscle preservation on GLP-1s remain:
- Hit your protein target — 0.7-1.0 g per pound of goal body weight per day. See our protein guide for specifics.
- Strength train 2-3 times per week — resistance training is the single most effective tool for preserving muscle. Our GLP-1 exercise guide has a full plan.
- Do not over-restrict calories — a moderate deficit (300-500 calories below maintenance) preserves more muscle than aggressive restriction.
- Spread protein across meals — aim for 25-40 g of protein per meal to maximize muscle protein synthesis.
For a complete strategy, see our guide to preventing muscle loss on GLP-1s.
If You Are Curious About Pipeline Drugs
Apitegromab joins bimagrumab as a leading candidate in the muscle preservation space. Both are in phase 2 trials. Neither is approved. The earliest either could realistically reach the market is 2028-2029 if all trials go well.
Other pipeline drugs worth watching: retatrutide (TRIUMPH-1 showing up to 28% weight loss), survodutide (MASH and obesity), and the monthly shots from Pfizer and Amgen.
The Bottom Line
Apitegromab is the most compelling muscle preservation candidate tested with GLP-1s to date. The EMBRAZE trial showed a clear signal: 1.9 kg more lean mass preserved, 55% better retention, no safety concerns.
But it is years from being available. For now, protein, strength training, and a moderate calorie deficit remain your best tools.
If you are worried about muscle loss on Mounjaro or other GLP-1s, focus on what you can control today. The pipeline drugs are promising — but they are not here yet.
This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before making changes to your diet, exercise, or medication routine. Apitegromab is an investigational drug and is not FDA-approved. Clinical data cited is from a phase 2 trial and subject to change.
